Speakers: Mira Pochron PhD (Head of Translational Biology, Global Blood Therapeutics)
Organizers: Dennis Hu, Cyrus Khojasteh and Dewakar Sangaraju (all of Genentech)
Date: 2021-02-16
Time: 12:00-13:30 Pacific Time
Registration fee: (USD):
Location: Online via Zoom
Major Sponsor: (1)Agilent
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2021-02-15  (it will close sooner if the seating cap is reached)

About the Topic

Building upon nearly 70 years of research in sickle cell disease (SCD) pathology, voxelotor, an HbS polymerization inhibitor, was developed to treat

the root cause of SCD pathophysiology. In 2019, the FDA granted Oxbryta® (Voxelotor) accelerated approval using hemoglobin, a biologic surrogate endpoint, indicative of reduced SCD hemolysis. In this presentation, we will share the R&D journey of Oxbryta®.

This presentation is part of the symposium series “Success Stories of Recently Approved Drugs and Lessons Learned”, jointly organized by PBSS and CLSA (California Life Science Association, a trade association representing California’s life science industry).

Mira Pochron, PhD

Staff Scientist, Head of Translational Biology

Global Blood Therapeutics, Inc

Dr. Mira Pochron currently serves as the Head of Translational Biology at Global Blood Therapeutics (GBT). During her tenure at GBT she was an integral part of developing and overseeing the collection of pharmacodynamic data in the phase 1/2a studies with voxelotor and continues to oversee the collection of pharmacodynamic and biomarker data. She has been with GBT since it’s early days in 2011 and been a core team member involved in assay development, compound screening and animal studies with Hb modifiers, such as voxelotor. Dr. Pochron received her Ph.D. in Chemistry and Biochemistry from University of California, Santa Cruz.